|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Aventis_Behring
gptkb:ZLB_Bioplasma
|
|
gptkbp:CEO
|
gptkb:Paul_Perreault
|
|
gptkbp:focusesOn
|
rare and serious diseases
|
|
gptkbp:formerName
|
gptkb:Aventis_Behring
gptkb:ZLB_Behring
|
|
gptkbp:founded
|
1904
|
|
gptkbp:headquartersLocation
|
gptkb:King_of_Prussia,_Pennsylvania,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CSL Behring
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Bill_Mezzanotte
gptkb:Paul_Perreault
|
|
gptkbp:manufacturingFacilities
|
gptkb:Argentina
gptkb:Australia
gptkb:Austria
gptkb:Brazil
gptkb:China
gptkb:Egypt
gptkb:France
gptkb:Germany
gptkb:Hungary
gptkb:India
gptkb:Italy
gptkb:Japan
gptkb:Mexico
gptkb:Russia
gptkb:Saudi_Arabia
gptkb:South_Korea
gptkb:Spain
gptkb:Sweden
gptkb:Switzerland
gptkb:Turkey
gptkb:United_Arab_Emirates
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:numberOfEmployees
|
over 25,000
|
|
gptkbp:operatesIn
|
global
|
|
gptkbp:parentCompany
|
gptkb:CSL_Limited
|
|
gptkbp:products
|
albumin
coagulation therapies
immunoglobulins
plasma-derived therapies
recombinant therapies
specialty biotherapeutics
|
|
gptkbp:specializesIn
|
immunology
neurology
critical care
hematology
respiratory
transplant
|
|
gptkbp:stockExchange
|
ASX (as part of CSL Limited)
|
|
gptkbp:subsidiary
|
gptkb:CSL_Limited
|
|
gptkbp:website
|
https://www.cslbehring.com/
|
|
gptkbp:bfsParent
|
gptkb:CSL
|
|
gptkbp:bfsLayer
|
5
|